Introducing the Predictive Oncology ACE program
Welcome to the ACE (Accelerating Compound Exploration) program, an initiative we are launching at Predictive Oncology to help academic and research institutions to advance their drug discovery. Our company created ACE to grant early-stage academic drug development groups and technology transfer offices access to the company’s PEDAL platform. PEDAL pairs active machine learning with an extensive biobank of 150K privately held tumor samples and in vitro assay results to help evaluate drug compounds and enable more informed selection of drug-tumor type combinations
Be a part of PEDAL
Compounds selected for the ACE program will be included in PEDAL campaigns with shared non-exclusive rights to the resultant tumor response data. Participation will be provided at no up-front cost to the investigator or institution.
Applications are being accepted here through March 31 for the first phase of the ACE program.
Additional information about Predictive Oncology’s technology and the submission process can be found here.